Bicycle Therapeutics plc — Form 8-K Summary
Reporting date: September 26, 2019; the filing was signed September 30, 2019. The filing reports executive employment agreements and an amendment to the non-employee director compensation policy. It does not provide operating or financial results for a reporting period.
Executive Compensation and Employment Agreements
- Kevin Lee, Chief Executive Officer: Amended and restated service agreement with wholly owned subsidiary BicycleTx Ltd. Base salary is $575,000 annually, with eligibility for an annual performance bonus of up to 50% of salary, payable in cash or equity based on specified corporate, strategic, regulatory and clinical objectives.
- Dr. Lee previously received a £150,000 retention bonus, repayable if he terminates employment before August 1, 2020. His employment has no specified term and generally requires six months’ notice for termination.
- Termination provisions include severance of one times annual salary plus up to 12 months of benefits outside a change-of-control period, or 1.5 times annual salary and target bonus plus up to 18 months of benefits following a qualifying termination within 12 months after a change of control. Certain time-based equity awards would accelerate in the latter circumstance.
- Lee Kalowski, President and Chief Financial Officer: Amended and restated employment agreement with wholly owned subsidiary Bicycle Therapeutics Inc. Base salary is $450,000 annually, with a target annual performance bonus of 40% of salary.
- Mr. Kalowski’s employment is at will. Qualifying termination provisions provide nine months of continued salary and health coverage outside a change-of-control period, or 12 months of salary, target bonus, health coverage and accelerated time-based equity awards following a qualifying termination within 12 months after a change of control.
Director Compensation Policy
The Board amended the non-employee director compensation policy. Initial grants will cover options to purchase 23,798 ordinary shares and will vest monthly over three years. Annual grants will cover 11,899 shares for continuing non-chair directors and 23,798 shares for the chair, with annual grants vesting in full on the grant date. Grants vest in full upon a sale of the Company.
Financial Metrics and Liquidity
The filing does not provide revenue, profit or loss, cash flow, margins, debt, cash balances, liquidity measures, or other operating financial metrics. It also does not provide financial guidance or an earnings outlook.
Material Changes, Risks and Unusual Items
- The principal reported changes are the amended executive agreements and revised director option-vesting provisions.
- The agreements create potential future cash, benefit and equity-acceleration obligations upon specified terminations, particularly following a change of control.
- Performance bonuses are contingent on achievement of goals, including regulatory and clinical milestones; the filing does not quantify expected payments.
- The filing states that the descriptions are qualified in their entirety by the full agreements filed as Exhibits 10.1 and 10.2.
Key Facts for Investor Verification
- Review Exhibits 10.1 and 10.2 for the complete definitions of Cause, Good Reason, Disability and Change of Control, as well as detailed termination provisions.
- Assess the potential dilution and accounting expense associated with executive and director equity awards.
- Monitor change-of-control exposure, including severance, benefits continuation and equity acceleration.
- Confirm future filings for any changes to executive compensation, director grants or employment status.